TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Significant Increase in Short Interest

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 46,900 shares, an increase of 47.5% from the November 15th total of 31,800 shares. Based on an average daily trading volume, of 42,200 shares, the short-interest ratio is presently 1.1 days. Approximately 1.7% of the shares of the company are short sold.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Highbridge Capital Management LLC acquired a new stake in TriSalus Life Sciences in the 2nd quarter valued at approximately $1,184,000. Duquesne Family Office LLC increased its holdings in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares during the period. Geode Capital Management LLC raised its stake in shares of TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares in the last quarter. Wolverine Asset Management LLC acquired a new stake in TriSalus Life Sciences in the second quarter worth about $240,000. Finally, MSD Partners L.P. bought a new position in TriSalus Life Sciences in the 3rd quarter valued at about $184,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

TriSalus Life Sciences Trading Down 1.5 %

TriSalus Life Sciences stock traded down $0.06 during midday trading on Friday, reaching $3.91. 19,841 shares of the stock traded hands, compared to its average volume of 39,728. TriSalus Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $10.42. The firm has a market cap of $119.22 million, a price-to-earnings ratio of -1.57 and a beta of 0.56. The firm has a fifty day moving average price of $4.19 and a two-hundred day moving average price of $5.07.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TLSI. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Canaccord Genuity Group dropped their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Northland Securities initiated coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective on the stock. Finally, Oppenheimer initiated coverage on TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 target price for the company. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $12.08.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.